EPHA3 (Ab-602) Antibody

What is EPHA3 and what biological functions does it regulate?

EPHA3 is a receptor tyrosine kinase that belongs to the EPH family. It functions as a membrane receptor that binds promiscuously to membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling . The signaling pathway downstream of the receptor is referred to as forward signaling, while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. EPHA3 shows high promiscuity for ephrin-A ligands with preferential binding to EFNA5 .

Upon activation by EFNA5, EPHA3 regulates several crucial cellular processes including cell-cell adhesion, cytoskeletal organization, and cell migration. It plays significant roles in cardiac cell migration and differentiation, and regulates the formation of the atrioventricular canal and septum during development through activation by EFNA1. EPHA3 is also involved in the retinotectal mapping of neurons and may control the segregation (but not guidance) of motor and sensory axons during neuromuscular circuit development .

What are the technical specifications of the EPHA3 (Ab-602) Antibody?

EPHA3 (Ab-602) Antibody is a rabbit polyclonal IgG antibody with the following specifications:

This antibody has been specifically validated for ELISA and Western blot applications with demonstrated efficacy in detecting EPHA3 in extracts from Jurkat cells .

How should researchers optimize Western blot protocols when using EPHA3 (Ab-602) Antibody?

For optimal Western blot results with EPHA3 (Ab-602) Antibody, researchers should:

• Begin with a dilution range of 1:500-1:3000 and optimize based on signal intensity and background levels .

• Extract proteins using buffers compatible with receptor tyrosine kinases, ideally containing phosphatase inhibitors if phosphorylated forms are of interest.

• Separate proteins on 8% SDS-PAGE gels, which are appropriate for the 110 kDa molecular weight of EPHA3 .

• Use nitrocellulose membranes for transfer, as demonstrated in successful protocols .

• Block membranes in 5% powdered milk in Tris-buffered saline-0.5% Tween 20 .

• Detect using an appropriate secondary antibody such as horseradish peroxidase-conjugated anti-rabbit IgG.

• Visualize using enhanced chemiluminescence systems .

This protocol has been validated in multiple studies and should provide specific detection of EPHA3 in human, mouse, and rat samples .

What cell and tissue types are appropriate for studying EPHA3 expression?

Based on research findings, appropriate experimental models for studying EPHA3 expression include:

• Jurkat cells, which have been successfully used for Western blot validation of the EPHA3 (Ab-602) antibody .

• Embryonic tissues, particularly spinal cord samples, which have been used to study EPHA3 expression during development .

• Tumor cells and surrounding microenvironment in various cancer types, especially lung adenocarcinoma, where EPHA3 mutations and expression changes have been extensively documented .

• Bone marrow-derived cells with mesenchymal and myeloid phenotypes, particularly those with EphA3+/CD90+/Sca1+ markers, which have shown relevant EPHA3 expression .

• Cardiac tissue during development, where EPHA3 plays a role in cell migration and differentiation .

• Neural tissues involved in retinotectal mapping and neuromuscular junction formation .

These models provide opportunities to investigate EPHA3's diverse roles in normal development and pathological conditions, particularly in cancer .

How do cancer-associated EPHA3 mutations affect its function in tumor biology?

Cancer genome sequencing has identified EPHA3 as one of the most frequently mutated genes in lung cancer, with mutations present in 5-10% of lung adenocarcinomas . The functional impact of these mutations presents a complex picture:

• At least two cancer-associated EPHA3 somatic mutations function as dominant inhibitors of the normal (wild type) EPHA3 protein .

• Wild-type EPHA3 demonstrates tumor-suppressive properties when reexpressed in human lung cancer cell lines:

  • It increases apoptosis by suppressing AKT activation in vitro

  • It inhibits the growth of tumor xenografts (e.g., in H1299 cells, mean tumor volume with wild-type EPHA3 = 437.4mm³ vs control = 774.7mm³, p<0.001) .

• These tumor-suppressive effects can be overridden in trans by dominant negative EPHA3 somatic mutations discovered in patients with lung cancer .

• EPHA3 gene copy numbers and/or expression levels are decreased in tumors from large cohorts of patients with lung cancer (e.g., the gene was deleted in 157 of 371 [42%] primary lung adenocarcinomas) .

• A 27-gene EPHA3 mutation–associated gene signature has been identified that correlates with poor patient survival .

These findings suggest that EPHA3 can function as a tumor suppressor in lung cancer, and mutations may contribute to cancer progression by inhibiting this tumor-suppressive function. This presents both challenges and opportunities for targeting EPHA3 in cancer therapy .

What are the critical phosphorylation sites in EPHA3 and how do they regulate its activity?

Multiple studies have identified key tyrosine phosphorylation sites in EPHA3 that differentially regulate its kinase activity and downstream signaling:

These phosphorylation-dependent regulatory mechanisms provide multiple levels of control over EPHA3 signaling and offer potential targets for intervention in pathological conditions .

How can researchers effectively validate EPHA3 antibody specificity in experimental models?

Validating antibody specificity is critical for reliable research outcomes. For EPHA3 (Ab-602) and other EPHA3 antibodies, the following methodological approaches are recommended:

• Genetic knockout validation:

  • Generate EphA3 null mice through homologous recombination

  • Extract proteins from tissues (e.g., embryonic spinal cord) of wild-type and knockout animals

  • Perform Western blot analysis to confirm absence of signal in knockout samples .

• Inducible expression systems:

  • Use cell lines with doxycycline-inducible EphA3 expression

  • Compare antibody binding between induced and non-induced cells

  • This approach confirms the antibody recognizes the target protein only when it's expressed .

• Cross-reactivity testing:

  • Transfect cells with cDNAs encoding related proteins (e.g., EphA1, EphA2, EphA3, EphA4, EphA5, EphA7)

  • Perform whole-cell binding assays and FACS analysis

  • Discard antibodies showing cross-reactivity to other family members .

• Epitope mapping:

  • Use synthetic peptides or recombinant protein fragments

  • Determine if the antibody recognizes conformational or linear epitopes

  • This information helps predict which applications the antibody will be suitable for .

• Phosphorylation-specific validation:

  • For studying EPHA3 activation, use phosphorylation-specific antibodies alongside total EPHA3 antibodies

  • Validate with samples treated with phosphatase or with mutations at key phosphorylation sites .

These complementary approaches ensure comprehensive validation of antibody specificity, which is essential for accurate interpretation of experimental results .

What methodologies exist for studying EPHA3 signaling in the tumor microenvironment?

Investigating EPHA3 in the tumor microenvironment requires specialized approaches:

• Agonistic antibody activation studies:

  • Use agonistic α-EphA3 antibodies to activate EPHA3 in tumor stroma

  • Assess impacts on tumor growth, stromal integrity, and microvasculature

  • This approach has demonstrated that EPHA3 activation can inhibit tumor growth by disrupting tumor stroma and vasculature .

• Cell population identification:

  • Identify relevant EPHA3-expressing cells within the tumor microenvironment

  • Studies have found EPHA3 on bone marrow-derived cells with mesenchymal and myeloid phenotypes

  • Focus on EphA3+/CD90+/Sca1+ mesenchymal/stromal cells for mechanistic studies .

• Functional response characterization:

  • Measure cell contraction, cell-cell segregation, and apoptosis upon EPHA3 activation

  • These processes have been identified as key responses to EPHA3 signaling in stromal cells .

• Xenograft models with EPHA3 manipulation:

  • Subcutaneously inject tumor cells expressing wild-type or mutant EPHA3 into nude mice

  • Measure tumor growth over time (typically 3 weeks post-injection)

  • Calculate tumor volume using the formula: volume = length × width² × 0.52

  • Analyze tumor tissues for proliferation (Ki-67) and apoptosis (cleaved-caspase 3) .

• Combined genomic and mutational analyses:

  • Integrate data from cancer genome sequencing with functional studies

  • Use an EPHA3 mutation–associated gene signature to stratify patients

  • This approach can reveal clinically relevant correlations with patient survival .

These methodologies provide complementary insights into EPHA3's roles in the complex tumor microenvironment, which differs significantly from its functions in cancer cells themselves .

What protein engineering approaches can generate functional EPHA3 for biochemical studies?

For researchers needing purified EPHA3 protein for in vitro studies, sophisticated protein engineering approaches have been developed:

• Expressed protein ligation (EPL) method:

  • This semisynthetic approach generates milligram amounts of functional Eph tyrosine kinase receptors

  • The technique yields approximately 4 mg of pure, homogenous semisynthetic Eph receptor from 1 L of extracellular domain (ECD) expression media and 0.5 L of intracellular domain (ICD) expression media .

• Production of fusion proteins:

  • Express His-SUMO-EphA3/A4ICD-His fusion proteins in appropriate expression systems

  • Typical yields for EphA3 ICD fusion proteins are ~15 mg/L .

• Efficient processing:

  • Use SUMO protease to unmask the N-terminal cysteine residue

  • This generates reactive EphA3 and EphA4 ICD proteins with approximately 90% cleavage efficiency .

• Chemical ligation:

  • Mix the reactive Eph building blocks (ECD and ICD) in a 1:1 ratio

  • This results in approximately 50% chemical ligation yield .

• Quality control:

  • Validate protein activity using kinase assays

  • Confirm proper folding through binding studies with ephrin ligands or antibodies

  • Verify homogeneity by SDS-PAGE and mass spectrometry .

These approaches allow researchers to produce sufficient quantities of functional EPHA3 protein for structural studies, drug screening, and detailed biochemical characterization of receptor function and regulation .

How does EPHA3 function differ between normal development and cancer pathology?

EPHA3 exhibits context-dependent functions that differ significantly between developmental processes and cancer:

This dual nature of EPHA3 function highlights the complexity of receptor tyrosine kinase signaling and suggests that therapeutic strategies targeting EPHA3 must consider both its cell-autonomous and non-cell-autonomous roles .

What methodological approaches resolve contradictions in EPHA3 research findings?

The EPHA3 literature contains apparent contradictions, particularly regarding its role as both tumor promoter and tumor suppressor. Researchers can resolve these contradictions through:

• Context-specific analysis:

  • Separately analyze EPHA3 function in cancer cells versus stromal cells

  • Consider cell-type specific effects when interpreting results

  • Use conditional knockout or cell-type specific expression systems to dissect cell-autonomous versus non-cell-autonomous effects .

• Mutation-specific functional studies:

  • Characterize individual cancer-associated mutations rather than treating them as equivalent

  • Test mutations in both in vitro and in vivo models

  • Compare effects of mutations on kinase activity, protein-protein interactions, and cellular phenotypes .

• Signaling pathway resolution:

  • Determine which downstream pathways are activated in different contexts

  • Map phosphorylation-dependent protein interactions

  • Use phosphomimetic and phospho-null mutations to dissect signaling mechanisms .

• Integration of genomic and functional data:

  • Develop gene signatures associated with specific EPHA3 mutations

  • Correlate signatures with clinical outcomes

  • Validate findings across independent patient cohorts .

• Consideration of ligand availability:

  • Assess expression of ephrin ligands in the experimental system

  • Test effects of adding exogenous ligands versus antibody-mediated receptor clustering

  • Consider differences between ligand-dependent and ligand-independent signaling .

These methodological approaches have helped reveal that EPHA3 can function as a tumor suppressor in cancer cells while its activation in the tumor microenvironment can disrupt tumor growth support structures, reconciling seemingly contradictory findings .

How can EPHA3 (Ab-602) be used for therapeutic target validation studies?

EPHA3 (Ab-602) Antibody can be utilized in several ways to validate EPHA3 as a potential therapeutic target:

• Expression profiling in clinical samples:

  • Use EPHA3 (Ab-602) in immunohistochemistry on tissue microarrays

  • Quantify expression levels in various cancer types versus normal tissues

  • Correlate expression with clinical parameters and patient outcomes .

• Pathway analysis in cell models:

  • Employ the antibody in Western blot analyses to monitor EPHA3 expression and activation status

  • Examine downstream signaling effects, particularly on AKT pathway components

  • Use recommended dilutions (1:500-1:3000) for optimal results .

• Target validation in combination with genetic approaches:

  • Compare antibody staining between wild-type cells and those with EPHA3 knockdown/knockout

  • Analyze cells expressing wild-type versus mutant EPHA3

  • Correlate protein levels with functional endpoints like apoptosis, proliferation, and migration .

• Analysis of tumor microenvironment:

  • Identify EPHA3-expressing cells within the tumor stroma

  • Characterize their phenotype (e.g., mesenchymal, myeloid)

  • Assess the effects of EPHA3 activation on stromal integrity .

• Comparison with functional antibodies:

  • Use EPHA3 (Ab-602) alongside agonistic anti-EPHA3 antibodies

  • While EPHA3 (Ab-602) is primarily for detection, comparing its effects with functional antibodies can provide insights into receptor activation mechanisms

  • This comparison helps distinguish between detection tools and potential therapeutic agents .

This multi-faceted approach has revealed EPHA3 as a potential dual therapeutic target: directly in cancer cells where it may function as a tumor suppressor (requiring restoration of function) and in the tumor microenvironment where activation can disrupt stromal support structures .

What controls are essential when using EPHA3 (Ab-602) Antibody in experimental protocols?

For rigorous research using EPHA3 (Ab-602) Antibody, the following controls are essential:

• Positive controls:

  • Jurkat cell lysates, which have been validated for detection of EPHA3

  • Transfected cells overexpressing wild-type EPHA3

  • Tissues known to express EPHA3 (e.g., developing cardiac tissue) .

• Negative controls:

  • EPHA3 knockout or knockdown samples

  • Cell lines with confirmed absence of EPHA3 expression

  • Secondary antibody-only controls to assess background staining .

• Specificity controls:

  • Pre-absorption with immunizing peptide to confirm epitope specificity

  • Comparison with other validated anti-EPHA3 antibodies targeting different epitopes

  • Testing cross-reactivity with other EPH family members through parallel testing on cells expressing EphA1, EphA2, EphA4, etc. .

• Loading and normalization controls:

  • Housekeeping proteins (e.g., GAPDH, β-actin) for Western blot normalization

  • Total protein stains (e.g., Ponceau S) to verify equal loading

  • When studying phosphorylation, parallel blots for total EPHA3 protein .

• Stimulation controls:

  • Ephrin ligand treatment (particularly EFNA5, which preferentially binds EPHA3)

  • Positive control for phosphorylation (e.g., pervanadate treatment)

  • Time-course analysis to capture transient signaling events .

Implementing these controls ensures reliable and interpretable results when using EPHA3 (Ab-602) Antibody in research applications .

How should researchers troubleshoot common issues with EPHA3 immunodetection?

When troubleshooting immunodetection of EPHA3 using the (Ab-602) Antibody, consider these methodological adjustments:

• For weak or absent signal:

  • Optimize antibody concentration (try the full recommended range: 1:500-1:3000 for WB)

  • Increase protein loading (EPHA3 may be expressed at low levels in some tissues)

  • Enhance signal detection methods (e.g., use more sensitive ECL substrates)

  • Consider enrichment through immunoprecipitation before Western blotting .

• For high background:

  • Increase blocking stringency (5% milk or BSA in TBST)

  • Reduce primary antibody concentration

  • Extend washing steps (more washes and/or longer duration)

  • Use more dilute secondary antibody .

• For detecting phosphorylated EPHA3:

  • Include phosphatase inhibitors in all buffers

  • Use fresh samples (phosphorylation is often labile)

  • Consider stimulating with ephrin ligands to increase phosphorylation

  • Compare with phospho-specific antibodies if available .

• For size discrepancies:

  • EPHA3 should appear at approximately 110 kDa

  • Higher molecular weight bands may represent glycosylated forms

  • Lower bands might indicate degradation or alternative splicing

  • Use appropriate molecular weight markers and gel percentage (8% recommended) .

• For inconsistent results across experiments:

  • Standardize cell culture conditions (confluence, passage number)

  • Prepare fresh working solutions of antibody

  • Use consistent lot numbers when possible

  • Document exact protocols and any deviations .

These troubleshooting approaches address the most common technical challenges in EPHA3 immunodetection and should help researchers obtain reliable, reproducible results .

What emerging techniques show promise for studying EPHA3 function and signaling?

Several cutting-edge approaches are advancing EPHA3 research:

• CRISPR/Cas9 genome editing:

  • Generate precise mutations corresponding to cancer-associated variants

  • Create cell lines with fluorescently tagged endogenous EPHA3

  • Develop conditional knockout models for tissue-specific studies

  • These approaches allow study of EPHA3 at physiological expression levels .

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize EPHA3 clustering and localization

  • Live-cell imaging to track EPHA3 dynamics during signaling

  • FRET/FLIM to detect protein-protein interactions in real time

  • These methods provide spatial and temporal information about EPHA3 signaling .

• Phosphoproteomics:

  • Global analysis of phosphorylation changes upon EPHA3 activation

  • Identification of novel EPHA3 substrates and signaling partners

  • Quantitative assessment of pathway activation kinetics

  • This approach reveals the broader signaling network beyond known interactions .

• Single-cell technologies:

  • RNA-seq to identify cell populations expressing EPHA3 in heterogeneous tissues

  • CyTOF to simultaneously measure multiple proteins in EPHA3-expressing cells

  • Spatial transcriptomics to map EPHA3 expression in complex tissues

  • These methods address cellular heterogeneity in normal and diseased tissues .

• Structural biology approaches:

  • Cryo-EM to determine full-length EPHA3 receptor structure

  • Hydrogen-deuterium exchange mass spectrometry to study conformational changes

  • Molecular dynamics simulations to predict effects of mutations

  • These techniques provide mechanistic insights into receptor activation and inhibition .

These emerging approaches promise to deepen our understanding of EPHA3 biology and may reveal new opportunities for therapeutic intervention in cancer and other diseases .

How might EPHA3 research evolve to address current knowledge gaps?

Future EPHA3 research should address several key knowledge gaps:

• Resolving context-dependent functions:

  • Develop models that separate cell-autonomous and non-cell-autonomous effects

  • Create tissue-specific and inducible expression systems

  • Employ single-cell approaches to distinguish effects on different cell populations

  • These strategies will clarify why EPHA3 can be both tumor-promoting and tumor-suppressive .

• Understanding mutation-specific mechanisms:

  • Conduct comprehensive functional characterization of all cancer-associated mutations

  • Determine which mutations affect kinase activity versus protein-protein interactions

  • Identify mutation-specific downstream signaling effects

  • This work will distinguish driver from passenger mutations and guide therapeutic approaches .

• Exploring therapeutic implications:

  • Develop strategies to restore wild-type EPHA3 function in cancer cells

  • Design approaches to target EPHA3 in the tumor microenvironment

  • Create combination therapies that address both aspects of EPHA3 biology

  • These therapeutic advances could exploit EPHA3's dual role in cancer .

• Mapping the complete EPHA3 interactome:

  • Identify all binding partners in different cellular contexts

  • Determine how phosphorylation regulates these interactions

  • Assess how cancer mutations alter the interactome

  • This comprehensive approach will reveal the full complexity of EPHA3 signaling .

• Integrating with other signaling pathways:

  • Explore cross-talk between EPHA3 and other receptor tyrosine kinases

  • Investigate integration with non-receptor pathways (e.g., G-protein coupled receptors)

  • Determine how EPHA3 contributes to global cellular decision-making

  • This systems biology perspective will place EPHA3 in broader signaling networks .

By addressing these knowledge gaps, researchers will develop a more complete understanding of EPHA3 biology with important implications for developmental biology, cancer biology, and targeted therapeutics .